Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Longboard Pharmaceuticals (LBPH) Stock Forecast & Price Target

Longboard Pharmaceuticals logo
Get the Latest News and Ratings for LBPH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Longboard Pharmaceuticals and its competitors.

Sign Up

LBPH Analyst Ratings Over Time

TypeCurrent Forecast
1/22/24 to 1/21/25
1 Month Ago
12/23/23 to 12/22/24
3 Months Ago
10/24/23 to 10/23/24
1 Year Ago
1/22/23 to 1/22/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$63.00$59.56$59.56$32.17
Forecasted Upside5.04% Upside-0.71% Downside0.01% Upside28.56% Upside
Consensus Rating
Hold
Hold
Hold
Buy

LBPH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LBPH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Longboard Pharmaceuticals Stock vs. The Competition

TypeLongboard PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.38
2.82
2.52
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside5.04% Upside24,936.03% Upside11.17% Upside
News Sentiment Rating
Neutral News

See Recent LBPH News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/15/2024HC Wainwright
2 of 5 stars
P. Trucchio
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$80.00 ➝ $60.00+1.56%
10/15/2024Truist Financial
2 of 5 stars
J. Lee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$60.00 ➝ $60.00+1.83%
10/14/2024Wedbush
4 of 5 stars
L. Chico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
10/14/2024B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Patel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$45.00 ➝ $60.00+1.95%
10/14/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Schimmer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral
8/26/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$80.00 ➝ $80.00+119.00%
8/2/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$45.00 ➝ $50.00+53.99%
7/11/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$36.00 ➝ $60.00+62.12%
1/2/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$16.00 ➝ $32.00+72.51%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:18 PM ET.


LBPH Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Longboard Pharmaceuticals is $63.00, with a high forecast of $90.00 and a low forecast of $44.00.

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Longboard Pharmaceuticals in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" LBPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LBPH, but not buy additional shares or sell existing shares.

According to analysts, Longboard Pharmaceuticals's stock has a predicted upside of 5.04% based on their 12-month stock forecasts.

Analysts like Longboard Pharmaceuticals less than other "medical" companies. The consensus rating for Longboard Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LBPH compares to other companies.


This page (NASDAQ:LBPH) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners